ArticleBreast cancer research and treatment2025
The feasibility and safety of fasting-mimicking diet in breast cancer patients with chemotherapy in China.
Article in Breast cancer research and treatment, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Intersection of Precision Nutrition and Bladder Cancer: A Narrative State-of-the-Art Review of Potential Applications and Challenges.Journal of clinical medicine · 2026Review
- Gut Microbiota and Nutritional Profiles of Colon Cancer Patients Undergoing Chemotherapy: A Longitudinal Pilot Study.Nutrients · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
purposeThe Fasting-Mimicking Diet (FMD) has emerged as a promising approach for mitigating the side effects and enhancing the efficacy of chemotherapy in cancer patients, while it is still challenging to implement FMD in clinical setting due the concern of nutritional supplements. This study is aimed to evaluate the feasibility of a recipe-based FMD among breast cancer (BC) patients, and assessing its effects on metabolic health and body composition.
methodsThis is a single-arm, pilot clinical trial involving BC patients undergoing chemotherapy. Participants were required to adhere to the FMD recipes for four days prior to and on the day of each chemotherapy cycle, which provided 34-54% of the normal caloric intake, with a total of three cycles needed for the study. FMD-related adverse events, body composition, and serum samples were monitored.
resultsA total of 30 participants were enrolled, and 27 of them completed 3 cycles of the FMD. The incidence of grade III or worse FMD-related adverse effects was 5.95% (5/84). A decline in IGF-1 compared to baseline was observed to be statistically significant at the end of the first FMD (B = - 23.29, p = 0.001) and second FMD (B = - 16.20, p = 0.023), but no statistical difference at the end of the third FMD (B = - 8.372, p = 0.327). After 3 FMD cycles and a 21-day washout, BC patients experienced a statistically significant reduction in body mass (- 2.04kg, 95% CI - 2.86, - 1.21 kg; p < 0.001), fat mass (- 1.88kg, 95% CI - 2.72, - 1.05 kg, p < 0.001), visceral fat area (- 14.78%, 95% CI - 21.13, - 8.43%, p < 0.001) and waist circumference (- 4.01,95% CI - 6.18, - 1.83, p < 0.001), while muscle mass remained stable (- 0.05 kg, 95% CI - 0.36, 0.27 kg; p = 0.270).
conclusionThe recipe-based FMD program is well-tolerated by BC patients. It is proved to be safe, with few or no fasting-related adverse effects and an acceptable magnitude of weight loss. Additionally, it is effective in reducing IGF1, indirectly correlating to insulin resistance and inflammation that could enhance efficacy of anticancer therapies.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.